SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that Jacob Chacko, M.D., its Chief Financial Officer, will make a presentation at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27, 2016, at 9:30 a.m. Eastern time (6:30 a.m. Pacific time) in New York, NY, and will discuss Ignyta’s Rx/Dx approach and review recent updates from ongoing clinical trials of the company’s robust pipeline of molecularly targeted therapies.
A webcast of the presentation will be available during the presentation in the Investors section of the company's website at http://investor.ignyta.com, and will be archived and available at that site for 14 days.
About Ignyta, Inc.
At Ignyta, we work tirelessly on behalf of cancer patients to offer potentially life-saving, precisely targeted therapeutics (Rx) guided by companion diagnostic (Dx) tests. Our integrated Rx/Dx strategy allows us to enter uncharted territory, illuminating the molecular drivers of cancer and quickly advancing treatments to address them. This approach embraces even those patients with the rarest cancers, who have the highest unmet need and who may otherwise not have access to effective treatment options. We are blazing a new future for cancer patients with our pipeline of first-in-class and best-in-class precision medicines - with the ultimate goal of not just shrinking tumors, but eradicating cancer relapse and recurrence in precisely defined patient populations.
For more information, please visit: www.ignyta.com.